المؤلفون: Fatehi, Pegah, Mahboubi-Fooladi, Zahra, Dastmardi, Maedeh, Jafarzadeh Esfehani, Reza, Khameneh Bagheri, Arash

المصدر: Journal of Medical Imaging & Radiation Sciences; Sep2023, Vol. 54 Issue 3, p446-450, 5p

مصطلحات موضوعية: BREAST ultrasound, RESEARCH, CROSS-sectional method, IMMUNOHISTOCHEMISTRY, MAMMOGRAMS, CELL receptors, ESTROGEN receptors, DUCTAL carcinoma, BREAST cancer, DESCRIPTIVE statistics, STATISTICAL correlation, BREAST tumors, PROGESTERONE receptors, BLOOD

Abstract (English): Breast cancer is the most common malignancy among women, and subtypes are mainly defined based on hormone receptors such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). The relationship between breast cancer subtypes and imaging features in mammography and sonography has been studied but the results are controversial. The purpose of this study was to determine the relationship between the hormonal receptor status of breast tumors and the radiologic feature of the tumors on mammography and sonography. Eighty patients with breast cancer enrolled in this cross-sectional study. ER, PR, and HER2 determined by immunohistochemistry. Every patient underwent mammography and sonography before the biopsy. We evaluated the relationship between the hormonal receptor status and radiographic features of tumors on breast sonography and mammography. The majority of the patients (n=75 (93.8%)) were diagnosed with invasive ductal carcinoma (IDC). The mean and standard deviation of the age was 49 ± 9 years. There was no significant relationship between the hormonal receptor status and the sonographic margin and shape (P>0.05). However, PR (P=0.002) and ER (P=0.001) status were significantly correlated with posterior features on sonography. ER-positive patients were more likely to have indistinct or speculated masses on mammography (P=0.017). Irregular or oval masses on mammography were higher in patients with ER (p=0.032). There was a significant correlation between PR and ER status and posterior features on sonography. Positive ER was associated with indistinct or speculated masses on mammography, as well as irregular or oval masses. [ABSTRACT FROM AUTHOR]

Abstract (French): Le cancer du sein est la tumeur maligne la plus fréquente chez les femmes, et les sous-types sont principalement définis en fonction des récepteurs hormonaux tels que le récepteur des œstrogènes (ER), le récepteur de la progestérone et le récepteur du facteur de croissance épidermique humain (HER2). La relation entre les sous-types de cancer du sein et les caractéristiques d'imagerie de la mammographie et de l'échographie a été étudiée, mais les résultats sont controversés. L'objectif de cette étude était de déterminer la relation entre le statut des récepteurs hormonaux des tumeurs mammaires et les caractéristiques radiologiques des tumeurs à la mammographie et à l'échographie. Quatre-vingts patientes atteintes d'un cancer du sein ont participé à cette étude transversale. Les récepteurs ER, PR et HER2 ont été déterminés par immunohistochimie. Chaque patiente a subi une mammographie et une échographie avant la biopsie. Nous avons évalué la relation entre le statut des récepteurs hormonaux et les caractéristiques radiographiques des tumeurs à l'échographie et à la mammographie. La plupart des patientes, 75 (93,8 %), ont reçu un diagnostic de carcinome canalaire invasif (CDI). L'âge moyen et l'écart-type étaient de 49 ± 9 ans. Il n'y avait pas de relation significative entre le statut des récepteurs hormonaux et la marge et la forme échographiques (P>0,05). Cependant, les statuts PR (P=0,002) et ER (P=0,001) étaient significativement corrélés avec les caractéristiques postérieures à l'échographie. Les patientes ER positives étaient plus susceptibles d'avoir des masses indistinctes ou spiculées à la mammographie (P=0,017). Les masses irrégulières ou ovales à la mammographie étaient plus nombreuses chez les patientes ER (p=0,032). Il existe une corrélation significative entre le statut PR et ER et les caractéristiques postérieures à l'échographie. Une RE positive était associée à des masses indistinctes ou spiculées à la mammographie, ainsi qu'à des masses irrégulières ou ovales. [ABSTRACT FROM AUTHOR]

: Copyright of Journal of Medical Imaging & Radiation Sciences is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Peters, A.L., Hall, P.S., Jordan, L.B., Soh, F.Y., Hannington, L., Makaranka, S., Urquhart, G., Vallet, M., Cartwright, D., Marashi, H., Elsberger, B.

المصدر: Breast; Jun2024, Vol. 75, pN.PAG-N.PAG, 1p

مصطلحات موضوعية: CLINICAL decision support systems, BREAST cancer, DISEASE risk factors, PROGESTERONE receptors, MULTIVARIATE analysis

مصطلحات جغرافية: SCOTLAND

الشركة/الكيان: GREAT Britain. National Health Service

مستخلص: The Oncotype DX Breast RS test has been adopted in Scotland and has been the subject of a large population-based study by a Scottish Consensus Group to assess the uptake of the recurrence score (RS), evaluate co-variates associated with the RS and to analyse the effect it may have had on clinical practice. Materials & Methods: Pan-Scotland study between August 2018–August 2021 evaluating 833 patients who had a RS test performed as part of their diagnostic pathway. Data was extracted retrospectively from electronic records and analysis conducted to describe change in chemotherapy administration (by direct comparison with conventional risk assessment tools), and univariate/multivariate analysis to assess relationship between covariates and the RS. Chemotherapy treatment was strongly influenced by the RS (p < 0.001). Only 30 % of patients received chemotherapy treatment in the intermediate and high risk PREDICT groups, where chemotherapy is considered. Additionally, 55.5 % of patients with a high risk PREDICT had a low RS and did not receive chemotherapy. There were 17 % of patients with a low risk PREDICT but high RS who received chemotherapy. Multivariate regression analysis showed the progesterone receptor Allred score (PR score) to be a strong independent predictor of the RS, with a negative PR score being associated with high RS (OR 4.49, p < 0.001). Increasing grade was also associated with high RS (OR 3.81, p < 0.001). Classic lobular pathology was associated with a low RS in comparison to other tumour pathology (p < 0.01). Nodal disease was associated with a lower RS (p = 0.012) on univariate analysis, with menopausal status (p = 0.43) not influencing the RS on univariate or multivariate analysis. Genomic assays offer the potential for risk-stratified decision making regarding the use of chemotherapy. They can help reduce unnecessary chemotherapy treatment and identify a subgroup of patients with more adverse genomic tumour biology. A recent publication by Health Improvement Scotland (HIS) has updated guidance on use of the RS test for NHS Scotland. It suggests to limit its use to the intermediate risk PREDICT group. Our study shows the impact of the RS test in the low and high risk PREDICT groups. The implementation across Scotland has resulted in a notable shift in practice, leading to a significant reduction in chemotherapy administration in the setting of high risk PREDICT scores returning low risk RS. There has also been utility for the test in the low risk PREDICT group to detect a small subgroup with a high RS. We have found the PR score to have a strong independent association with high risk RS. This finding was not evaluated by the key RS test papers, and the potential prognostic information provided by the PR score as a surrogate biomarker is an outstanding question that requires more research to validate. • Real-world data across NHS Scotland, providing insights into the implementation of genomic decision tools in the management of EBC • The RS test has caused significant decreases in chemotherapy use with benefits including reduced patient morbidity and cost savings for the NHS. • The PR score is a strong independent predictor of the RS with future integrated use with genomic tests an avenue of future research and validation. [ABSTRACT FROM AUTHOR]

: Copyright of Breast is the property of Churchill Livingstone, Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Chen, Haizhu, Gui, Xiujuan, Zhou, Ziwei, Su, Fengxi, Gong, Chang, Li, Shunrong, Wu, Wei, Rao, Nanyan, Liu, Qiang, Yao, Herui

المصدر: Breast; Jun2024, Vol. 75, pN.PAG-N.PAG, 1p

مصطلحات موضوعية: HER2 positive breast cancer, NEOADJUVANT chemotherapy, HORMONE receptor positive breast cancer, TREATMENT effectiveness, PROGESTERONE receptors, HORMONE receptors

مستخلص: The impact of distinct estrogen receptor (ER) and progesterone receptor (PR) expression patterns on tumor behavior and treatment outcomes within HER2-positive breast cancer is not fully explored. This study aimed to comprehensively examine the clinical differences among patients with HER2-positive breast cancer harboring distinct ER and PR expression patterns in the neoadjuvant setting. This retrospective analysis included 871 HER2-positive breast patients treated with neoadjuvant therapy at our hospital between 2011 and 2022. Comparisons were performed across the three hormone receptor (HR)-specific subtypes, namely the ER-negative/PR-negative/HER2-positive (ER-/PR-/HER2+), the single HR-positive (HR+)/HER2+, and the triple-positive breast cancer (TPBC) subtypes. Of 871 patients, 21.0% had ER-/PR-/HER2+ tumors, 33.6% had single HR+/HER2+ disease, and 45.4% had TPBC. Individuals with single HR+/HER2+ tumors and TPBC cases demonstrated significantly lower pathological complete response (pCR) rates compared to those with ER-/PR-/HER2+ tumors (36.9% vs. 24.3% vs. 49.2%, p < 0.001). Multivariate analysis confirmed TPBC as significantly associated with decreased pCR likelihood (OR = 0.42, 95%CI 0.28–0.63, p < 0.001). Survival outcomes, including disease-free survival (DFS) and overall survival (OS), showed no significant differences across HR-specific subtypes in the overall patient population. However, within patients without anti-HER2 therapy, TPBC was linked to improved DFS and a trend towards better OS. HER2-positive breast cancer exhibited three distinct HR-specific subtypes with varying clinical manifestations and treatment responses. These findings suggest personalized treatment strategies considering ER and PR expression patterns, emphasizing the need for further investigations to unravel molecular traits underlying HER2-positive breast cancer with distinct HR expression patterns. • HER2-positive breast cancer reveals three distinct HR-specific subtypes. • TPBC exhibits lower pCR rates than ER-/PR-/HER2+ tumors or single HR+/HER2+ cases. • TPBC is independently associated with decreased likelihood of achieving pCR. • No significant differences were observed in DFS and OS across HR-specific subtypes in the overall population. • TPBC was associated with improved DFS and a trend towards better OS in the absence of anti-HER2 therapy. [ABSTRACT FROM AUTHOR]

: Copyright of Breast is the property of Churchill Livingstone, Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Suzuki, Satoshi, Kitamura, Hidetomo, Hayashi, Kohtaro, Nakashima, Tomomi, Okamura, Masaru, Shirai, Katsuaki, Kariya, Takuro

المصدر: Journal of Comparative Pathology; Nov2021, Vol. 189, p45-51, 7p

مصطلحات موضوعية: ENDOMETRIAL hyperplasia, ENDOMETRIAL diseases, HISTOPATHOLOGY, CAT diseases, SURVIVAL rate, PRECANCEROUS conditions, PROGESTERONE receptors

مستخلص: In humans, atypical endometrial hyperplasia (AEH) is considered as a precancerous lesion of endometrial adenocarcinoma (EA), from which it must be distinguished. Precancerous lesions have not been reported in cats with EA. We now document the histopathological features of endometrial lesions in six cats, which histopathologically resembled human AEH and had a good prognosis following ovariohysterectomy. Grossly, one cat presented with papillomatous nodules and three cats had pyometra. Histopathologically, proliferation of endometrial epithelial cells without atypia was observed in all cases. In some regions of the endometrium, cells had increased atypia and were arranged in stratified layers, which formed irregular ducts and papillary structures. No invasive behaviour or vascular invasion was observed. On the basis of these findings, the cats were diagnosed with non-invasive or early-stage adenocarcinoma. Immunohistochemistry for oestrogen receptor and progesterone receptor revealed an inverse correlation with the severity of the endometrial lesions and degree of malignancy of tumour cells. Ki67 labelling revealed that mitotic activity increased as the lesion developed. All cats survived, with a median survival time of 385 days (range: 229–744 days). The distribution of the histopathological endometrial changes and the non-invasive behaviour in these feline cases resemble cases of AEH in humans. [ABSTRACT FROM AUTHOR]

: Copyright of Journal of Comparative Pathology is the property of W B Saunders and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Pant, Ishita, Chaturvedi, Sujata, Tripathi, Chandra, Singh, Gurbachan

المصدر: International Journal of Health & Allied Sciences; Apr-Jun2019, Vol. 8 Issue 2, p116-122, 7p

مصطلحات موضوعية: PROGESTERONE receptors, CENTRAL nervous system tumors, CANCER invasiveness

الشركة/الكيان: WORLD Health Organization

مستخلص: BACKGROUND: Meningiomas are among the most common of central nervous system neoplasms. These are classified into meningiomas with low risk of recurrence and aggressive behavior (World Health Organization [WHO] Grade I) and meningiomas with greater likelihood of recurrence and aggressive behavior (WHO Grade II and Grade III) according to the WHO 2016 criteria. A host of markers are implicated in the genesis, progression, and recurrence of meningiomas. This study was undertaken with the aim to analyze the sociodemographic profile of various grades of meningiomas and to assess the relevance and correlation between progesterone receptor (PR), Ki67, and p53 among these. MATERIALS AND METHODS: Retrospective analysis was performed for 273 cases of intracranial and intraspinal meningiomas. All intracranial and intraspinal meningiomas were graded according to the WHO 2016 criteria. Immunohistochemistry was performed using PR, Ki67, and p53 in 273 cases. Statistical analysis was performed. RESULTS: According to the WHO 2016 grading system, 254 were Grade I (93.04%), 14 were Grade II (5.13%), and 5 were Grade III (1.83%) meningiomas. According to the histological type, among Grade I, 207 meningiomas were transitional (75.82%), 11 meningothelial (4.03%), 11 angiomatous (4.03%), 8 psammomatous (2.93%), 6 fibroblastic (2.19%), 5 microcystic (1.83%), 4 metaplastic (1.47%), and 2 secretory (0.73%). Among Grade II, there were 13 cases of atypical meningiomas (4.76%) and 1 case of clear-cell meningioma (0.37%). Among Grade III, 3 meningiomas were rhabdoid variant (1.09%) and 2 cases were anaplastic meningiomas (0.37%). In all the cases, correlation with PR, p53, and Ki67 was assessed. CONCLUSION: Immunohistochemical evaluation of PR status, p53 expression, and Ki67 labeling index do add information to the routine histopathological evaluation of meningiomas. In addition, these markers do help in assessing the biological behavior of meningiomas. [ABSTRACT FROM AUTHOR]

: Copyright of International Journal of Health & Allied Sciences is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Liao, G.-S., Hsu, H.-M., Chu, C.-H., Hong, Z.-J., Fu, C.-Y., Yu, J.-C., Dai, M.-S., Huang, T.-C., Chou, Y.-C.

المصدر: European Journal of Surgical Oncology; Oct2017, Vol. 43 Issue 10, p1855-1861, 7p

مصطلحات موضوعية: BREAST cancer treatment, ESTROGEN receptors, PROGESTERONE receptors, HER2 protein, IMMUNOHISTOCHEMISTRY, CANCER hormone therapy, HEALTH outcome assessment, SURVIVAL analysis (Biometry)

مستخلص: Background Recent publications have suggested that human epidermal growth factor receptor 2 (HER2)-negative breast cancers with “weak” estrogen receptor (ER)/progesterone receptor (PR) expression levels by immunohistochemical (IHC) analysis were considered as the triple-negative (TN) subtype. This study aimed to evaluate the overall survival (OS), disease-free survival rates (DFS), and disease-specific survival (DSS) based on ER and PR expression levels into one of three groups, ER and PR <1%, ER and PR 1%–20%, and ER or PR >20% by hormone therapy. Methods Medical records of 3353 breast cancer patients treated from 2006 to 2013 were retrospectively reviewed. Tumor characteristics, type of treatment, OS, DFS and DSS were evaluated among the three patient groups. Results Regarding OS, there were significant differences according to the received hormone therapy in the different groups: ER and PR <1% ( P = 0.972), ER and PR 1%–20% ( P = 0.264), and ER or PR >20% ( P = 0.014). Regarding DFS and DSS, there were also significant differences in the different groups: ER and PR <1% ( P = 0.611, 0.766), ER and PR 1%–20% ( P = 0.847, 0.629), and ER or PR >20% ( P = 0.031, 0.002). Conclusions In HER2 negative breast cancer patient with hormone therapy, ER and PR expression level of 1%–20% has similar survival outcome to the ER and PR expression level of <1% by IHC analysis. [ABSTRACT FROM AUTHOR]

: Copyright of European Journal of Surgical Oncology is the property of W B Saunders and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)